

JP Morgan Chase
Mr Peter Scher, Corporate Responsibility
Giulia Guidi, Global Environmental & Social Risk Management
Matthew Arnold, Head of Office of Environmental Affairs
270 Park Avenue
10017 New York, New York, United States

open letter

München 27 April 2015

Dear Ms Guidi, Mr Scher, Mr Arnold

Invitation to a Testbiotech conference in Berlin on patents on life,
genetic engineering and animal welfare

First of all, please let me introduce our organisation. Testbiotech was founded to monitor trends and assess risks in modern biotechnology. We promote diverse, critical and informed discussions on genetic engineering and biotechnology. The expertise we provide is independent of industry and aimed at promoting informed public discussion and choice. (For more information please see www.testbiotech.org).

On 17 June 2015, we are holding a conference on “The Patented Ape: New methods in genetic engineering, patents on life and the protection of humans and animals“, in Berlin, Germany. As ethical investment policies are on the agenda, we would very much like to invite you to attend this conference. For details please see the programme attached.

One of our main topics at the conference will be patents on animals used in experimental research. We are concerned that the European Patent Office in Munich has already granted around 1500 patents on animals used in biotechnology. Some of them even claim chimpanzees:

- EP1409646 held by Altor BioScience, USA, claims chimpanzees with a genetically engineered immune system;
- EP1364025 held by Bionomics, Australia, claims chimpanzees with a manipulated genome making them more likely to suffer from cancer, and EP 1852505 also held by Bionomics, Australia claims chimpanzees genetically engineered to suffer from epilepsy;

**TEST
BIOTECH**

Testbiotech e. V.
Institut für unabhängige
Folgenabschätzung in
der Biotechnologie

Frohschammerstraße 14
80807 München
Tel.: 0049 (0)
15154638040
Fax: 0 89 - 359 66 22
info@testbiotech.org
www.testbiotech.org

Geschäftsführung:
Dr. Christoph Then

Steuernummer:
143/222/75510

Sitz des Vereins:
München

Vereinsregister:
Amtsgericht München
VR 202119
Als gemeinnützig
anerkannt

- EP 1456346 and EP 1572862 held by Intrexon, USA, both claim chimpanzees genetically engineered with synthetic DNA originating from insects.

Other companies heavily engaging in filing patents on genetically engineered animals include Novartis, Hoffmann La Roche and Pfizer. As you can see from our programme, we will be presenting a report on the investors active in this field, including your own banking institute. Our research has shown that JP Morgan Chase amongst those financial institutions that have to carry a share of the responsibility in this context. It is a major shareholder of Intrexon, Novartis, Pfizer and LaRoche, all of which hold a number of patents on animals. Intrexon was invited to give a presentation at the JPMorgan Healthcare Conference earlier this year. For more details please see below.

We strongly believe that animals are our fellow creatures and, as such, they should be treated with the respect they deserve. Allowing patents on animals means that incentives are provided to conduct animal experiments for commercial reasons. Nobody should be investing to make a profit from animal suffering. And, more generally, animals should not be treated as if they were technical inventions. For this reason patents on animals, especially those claiming mammals or even great apes, should neither be filed by companies nor granted by patent offices.

Since you are one of the investors in this field we would very much welcome your participation at our conference. We are convinced that your bank is ready to play a constructive role in this dialog, helping to find constructive answers to the problems as outlined. Since we are very much aware of the rapid innovation and new applications in this field, we feel that it is vital to maintain and uphold high ethical standards in this field of investment. Please give us your point of view and take part in our discussions. We would also very much appreciate your comments on the findings from our research. If possible, please let us know your comments and notification of attendance at the conference till 1 June 2015.

We look forward to your response.

With kind regards



Dr. Christoph Then, Executive Director, Testbiotech

**TEST
BIOTECH**

Testbiotech e. V.
Institut für unabhängige
Folgenabschätzung in
der Biotechnologie

Annex:

Overview of affiliations between JP Morgan Chase and some relevant pharmaceutical companies

- **Intrexon**

JPMorgan is a major shareholder of Intrexon, holding USD 10,17 millions worth of shares (0.55 %) in 2014. JP Chase was also part of a 2013 share issuing syndicate, acquiring USD 96 million (out of 160 million), and in 2015 JPMorgan Securities, part of JPMorgan Chase, represented an issuing syndicate, for shares worth approx. USD 95 million. Intrexon was invited to give a presentation at the January 2015 JPMorgan Healthcare Conference.

- **Novartis**

JPMorgan is a major shareholder of Novartis, holding shares worth USD 1 billion (0.42 %) in 2013-2014. JPMorgan underwrote Novartis-bonds worth USD 400 million (2012) and USD 320 million USD (2014). William T. Winters, a member of the Novartis Board of Directors since 2013 and current member of the Compensation Committee served as co-CEO of JPMorgan's investment banking business from 2003 to 2010.

- **Pfizer**

JPMorgan is a major shareholder of Pfizer holding USD 1.7 billion worth of shares (0.91 %) in 2014. In 2014, JP Morgan Securities undersigned Pfizer bonds worth USD 753.8 million. JPMorgan is also part of syndicate of banks for a USD 7 billion loan to Pfizer (2013), itself committing USD 591 million. JPMorgan is currently acting as the arranger for another USD 7000 million loan (2014), and acted as one of the dealer managers in an share exchange offer with Zoetis (animal health company) (2013).

- **Roche Holding (Hoffmann-La Roche)**

JPMorgan is a key shareholder with USD 976.36 million worth of shares (0,42%) in 2013-2014. JPMorgan Securities, part of JPMorgan Chase, underwrote bonds worth USD 1,4 billion in May 2014, and USD 87.5 million as well as USD 216.7 million in November 2014.

**TEST
BIOTECH**

Testbiotech e. V.
Institut für unabhängige
Folgenabschätzung in
der Biotechnologie